Mayo Clinic Cancer Center (MCCC) Senior Leadership encompasses the Director, Deputy Director Clinical Affairs, Deputy Director MCCC Arizona, Deputy Director MCCC Florida, and 5 Associate Directors. There have been a number of changes since the last renewal. As part of a planned succession following the successful 2003 CCSG competitive renewal, Dr. Robert Diasio was recruited as Cancer Center Director in a national search initiated in mid 2005 culminating with his appointment effective September 1, 2006. Dr. Charles Erlichman, previously an MCCC Associate Director, was appointed Deputy Director for Clinical Affairs in late 2004. In his position as Deputy Director for Clinical Affairs, he has primary responsibility for overseeing and implementing integration of the Cancer Center's clinical research activities across all three sites. Also in late 2004, Dr. Robert Smallridge was formally appointed as Deputy Director for MCCC Florida;having previously been the acting Deputy Director. Dr. Rafael Fonseca, co-program leader of the Hematologic Malignancies Program, was appointed as Deputy Director for MCCC Arizona in July 2006 succeeding Dr. Laurence J. Miller who stepped down to focus on his responsibilities as Associate Dean for Research at Mayo Clinic and Director for Research at Mayo Clinic Arizona. Senior Leadership otherwise remains unchanged at the level of the Associate Directors with Dr. Ed Leof continuing as Associate Director for Basic Sciences, Dr. Gloria Petersen as Associate Director for Population Sciences, Dr. Robert Jenkins as Associate Director for Translational Research, Mr. Michael Pfenning as Associate Director for Administration and Dr. Lynn Hartmann as Associate Director for Education and Training. SENIOR/

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-35
Application #
7944846
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-17
Project End
2014-02-28
Budget Start
2009-04-17
Budget End
2010-02-28
Support Year
35
Fiscal Year
2009
Total Cost
$522,304
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393

Showing the most recent 10 out of 1086 publications